Department of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Providence Health & Services, Portland, OR, USA.
BMC Cancer. 2021 Aug 3;21(1):889. doi: 10.1186/s12885-021-08632-8.
Identifying ineffective practices that have been used in oncology is important in reducing wasted resources and harm. We sought to examine the prevalence of practices that are being used but have been shown in RCTs to be ineffective (medical reversals) in published oncology studies.
We cross-sectionally analyzed studies published in three high-impact oncology medical journals (2009-2018). We abstracted data relating to the frequency and characterization of medical reversals.
Of the 64 oncology reversals, medications (44%) represented the most common intervention type (39% were targeted). Fourteen (22%) were funded by pharmaceutical/industry only and 56% were funded by an organization other than pharmaceutical/industry. The median number of years that the practice had been in use prior to the reversal study was 9 years (range 1-50 years).
Here we show that oncology reversals most often involve the administration of medications, have been practiced for years, and are often identified through studies funded by non-industry organizations.
识别肿瘤学中已使用但已在 RCT 中证明无效的实践(医学反转)对于减少浪费资源和危害非常重要。我们试图研究在已发表的肿瘤学研究中使用但已在 RCT 中证明无效的实践(医学反转)的流行情况。
我们对三份高影响力肿瘤学医学期刊(2009-2018 年)发表的研究进行了横断面分析。我们提取了与医学反转的频率和特征有关的数据。
在 64 个肿瘤学反转中,药物(44%)代表最常见的干预类型(39%是靶向治疗)。有 14 项(22%)仅由制药/行业资助,56%由制药/行业以外的组织资助。在进行反转研究之前,该实践的使用年限中位数为 9 年(范围 1-50 年)。
在这里,我们表明肿瘤学反转最常涉及药物的使用,已经实践了多年,并且通常是通过非行业组织资助的研究来确定的。